Study Overview: This study looks at how well a medicine called avacopan works in kids aged 6 to under 18 who have a condition called AAV (anti-neutrophil cytoplasmic antibody-associated vasculitis). AAV is when the immune system mistakenly attacks small blood vessels. Kids in the study will get avacopan along with other treatments like rituximab or cyclophosphamide.
Eligibility: To join, participants must be between 6 and under 18 years old. They need to have a specific type of AAV called GPA (granulomatosis with polyangiitis) or MPA (microscopic polyangiitis). Kids must have signs of the disease and weigh at least 15 kg (about 33 pounds).
Key Points:
- Study involves taking avacopan with other medicines.
- Participants will need to attend multiple visits.
- There may be risks involved with the treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand